Aprogen Biologics Issues 50.8 Billion KRW Convertible Bonds to Repay Affiliate Debt; Severe Dilution Concerns for Existing Shareholders
Aprogen Biologics has decided to issue 50.8 billion KRW in unsecured private convertible bonds, equivalent to approximately 169% of its current market capitalization.
The bonds are issued to affiliates Aptochrom and Aprogen I&C, with payment made by offsetting existing loan receivables. All proceeds will be used to repay borrowings from these same affiliates.
The preliminary conversion price is 2,353 KRW, about 13% above the current stock price of 2,080 KRW. However, the price can be adjusted downward to as low as 1,648 KRW under anti-dilution provisions. Full conversion would add 21.59 million shares, a 149.8% increase over outstanding shares.
Including previously issued convertible bonds, total potential conversion shares reach 46.02 million, or 319.29% of outstanding shares, causing severe dilution. This significantly impairs existing shareholders' equity value.
[AI Summary]Aprogen Biologics is using a massive convertible bond issuance to affiliates to swap debt for equity without actual cash inflow. The resulting dilution, exceeding 1.5 times the current outstanding shares, is extremely negative for existing shareholders. Significant downward pressure on the stock price is expected.
KOSPI Filing Information
[Correction of Description] Report on Major Matters (Decision on Issuance of Convertible Bonds)